低MGMT数字表达与替莫唑胺治疗的IDH1野生型胶质母细胞瘤更好结局相关
该研究评估112例成人胶质母细胞瘤(GBM)福尔马林固定石蜡包埋标本,比较MGMT启动子甲基化与MGMT mRNA表达,并分析其与替莫唑胺(TMZ)疗效及患者结局的关系。结果显示MGMT表达与MGMT启动子甲基化水平呈负相关(-0.506,p<0.0001),MGMT低表达与更好生存显著相关,联合甲基化与表达可改善预后判断价值。
要点
- IDH1野生型GBM中MGMT启动子甲基化与TMZ更好反应显著相关。
- MGMT低mRNA表达与TMZ治疗GBM患者更好生存显著相关。
- 联合MGMT甲基化与mRNA表达可提高TMZ反应预测准确性。
核心结论
- MGMT mRNA数字表达水平与TMZ治疗的GBM患者结局相关,联合MGMT甲基化与mRNA表达或可更准确预测TMZ反应。
研究设计与样本
- 回顾性分析112例成人GBM的FFPE标本;IDH1与ATRX用免疫组化,TERT启动子热点突变用Sanger或焦磷酸测序,MGMT启动子甲基化用焦磷酸测序,MGMT mRNA用nCounter® Vantage 3D™ DNA损伤修复panel检测。
主要发现
- 112例GBM中96例IDH1野生型、16例IDH1突变型;IDH野生型中ATRX阳性表达91.6%(88/96),IDH突变型中43.7%(7/16)。
- IDH野生型中TERT启动子突变70.4%(50/71);MGMT启动子甲基化在IDH野生型为55.5%(35/63)、IDH突变型为84.6%(11/13)。
- MGMT启动子甲基化与TMZ更好反应显著相关;MGMT表达与MGMT启动子甲基化水平负相关(-0.506,p<0.0001),MGMT低表达与更好生存显著相关。
- 整合MGMT启动子甲基化与表达后,预后判断价值显著改善。
临床怎么用
- 对TMZ治疗的GBM患者,可结合MGMT启动子甲基化与MGMT mRNA表达评估TMZ反应与预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glioblastoma (GBM) is the deadliest primary brain tumor. The standard treatment consists of surgery, radiotherapy, and temozolomide (TMZ). TMZ response is heterogeneous, and MGMT promoter (MGMTp) methylation has been the major predictive biomarker. We aimed to describe the clinical and molecular data of GBMs treated with TMZ, compare MGMT methylation with MGMT expression, and further associate with patient's outcome. METHODS: We evaluate 112 FFPE adult GBM cases. IDH1 and ATRX expression was analyzed by immunohistochemistry, hotspot TERT promoter (TERTp) mutations were evaluated by Sanger or pyrosequencing, and MGMTp methylation was assessed by pyrosequencing and MGMT mRNA expression using the nCounter® Vantage 3D™ DNA damage and repair panel. RESULTS: Of the 112 GBMs, 96 were IDH1WT, and 16 were IDH1MUT. Positive ATRX expression was found in 91.6% (88/96) of IDHWT and 43.7% (7/16) of IDHMUT. TERTp mutations were detected in 70.4% (50/71) of IDHWT. MGMTp methylation was found in 55.5% (35/63) of IDHWT and 84.6% (11/13) of IDHMUT, and as expected, MGMTp methylation was significantly associated with a better response to TMZ. MGMT expression was inversely correlated with MGMTp methylation levels (- 0.506, p < 0.0001), and MGMT low expression were significantly associated with better patient survival. It was also observed that integrating MGMTp methylation and expression, significantly improved the prognostication value. CONCLUSIONS: MGMT mRNA levels evaluated by digital expression were associated with the outcome of TMZ-treated GBM patients. The combination of MGMT methylation and mRNA expression may provide a more accurate prediction of TMZ response in GBM patients.
引用
- Gomes I, Moreno DA, Dos Reis MB, et al. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide. J Neurooncol. 2021. PMID: 33400009. doi:10.1007/s11060-020-03675-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。